Cite
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
MLA
Iguchi, Taro, et al. “Enzalutamide with Androgen Deprivation Therapy in Japanese Men with Metastatic Hormone‐sensitive Prostate Cancer: A Subgroup Analysis of the Phase III ARCHES Study.” International Journal of Urology, vol. 28, no. 7, July 2021, pp. 765–73. EBSCOhost, https://doi.org/10.1111/iju.14568.
APA
Iguchi, T., Kimura, G., Fukasawa, S., Suzuki, H., Uemura, H., Nishimura, K., Matsumoto, H., Yokomizo, A., Armstrong, A. J., Rosbrook, B., Sugg, J., Baron, B., Chen, L., Kunieda, F., & Stenzl, A. (2021). Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. International Journal of Urology, 28(7), 765–773. https://doi.org/10.1111/iju.14568
Chicago
Iguchi, Taro, Go Kimura, Satoshi Fukasawa, Hiroyoshi Suzuki, Hiroji Uemura, Kazuo Nishimura, Hiroaki Matsumoto, et al. 2021. “Enzalutamide with Androgen Deprivation Therapy in Japanese Men with Metastatic Hormone‐sensitive Prostate Cancer: A Subgroup Analysis of the Phase III ARCHES Study.” International Journal of Urology 28 (7): 765–73. doi:10.1111/iju.14568.